Neuland Laboratories Reports Strong Q3 FY2025 Performance

Neuland Laboratories, a leading pharmaceutical company, has announced impressive financial results for the third quarter of fiscal year 2025. The company reported consolidated revenue from operations of 3.98 billion rupees, showcasing robust growth. Additionally, Neuland Labs posted a consolidated profit of 1.02 billion rupees, demonstrating strong profitability. This performance highlights the company's resilience and strategic positioning in the pharmaceutical sector. Investors and industry analysts are closely watching Neuland's continued success in navigating market challenges.

 

Source: Moneycontrol